Cellavision Ab (CLVSF) 3.3344 $CLVSF
CellaVision AB: Interim Report January-June 2014
Thomson Reuters ONE - Fri Jul 18, 1:20AM CDT
Continued strong sales growth of 50 percent
CellaVision acquires a new technology platform
Thomson Reuters ONE - Mon Jun 23, 8:01AM CDT
This information was released for public disclosure on June 23, 2014 at 3.00 pm CET.
CellaVision revises outlook for the full year: Sales growth in 2013
Thomson Reuters ONE - Wed Jan 15, 1:26AM CST
CellaVision announces that sales for the fourth quarter of 2013 has increased significantly in comparison with the corresponding quarter in 2012. This means that the company shows sales growth for the full year 2013, in contrast to what was communicated in the company's half-year report 2013.
CellaVision AB: Interim report January - June 2013
Thomson Reuters ONE - Wed Jul 17, 1:31AM CDT
Weak quarter but continued global market initiatives and sales successes in Asia
CellaVision appoints new heads of Quality Assurance and Scientific Affairs
Thomson Reuters ONE - Mon Jun 24, 1:31AM CDT
CellaVision, which develops and sells products for routine analysis of blood and other body fluids in health care services, strengthens its organization with new positions in quality and scientific affairs. Goran Granqvist has been appointed VP Quality, responsible for Quality Assurance and part of the management team. Hans-Inge Bengtsson takes a new role as Director Scientific Affairs.
Sweden's Equalis invests in CellaVision's new product for external quality assurance of laboratory tests in hematology
Thomson Reuters ONE - Tue May 07, 4:02AM CDT
CellaVision has signed an agreement with Equalis, the Swedish provider of external quality assessment for clinical laboratory tests. Equalis has chosen to invest in CellaVision's new proficiency testing program for the identification of cells in blood and other body fluids, CellaVision® Proficiency Software. The order comprises a license for 350 users.
Bulletin from the Annual General Meeting of CellaVision AB (publ) held on April 24, 2013
Thomson Reuters ONE - Wed Apr 24, 12:39PM CDT
CellaVision AB (publ) held its Annual General Meeting today, April 24, 2013, in Lund. The meeting resolved upon the following:
CellaVision AB: Interim report January - March 2013
Thomson Reuters ONE - Wed Apr 24, 7:02AM CDT
More sales channels increase our growth opportunities but the year got off to a weak start
CellaVision and Sysmex announce a jointly-developed product for hematology labs
Thomson Reuters ONE - Tue Apr 16, 8:01AM CDT
This information was released for public disclosure on April 16, 2013 at 3.00 pm CET.
CellaVision and Beckman Coulter enhance partnership by adding EMEA to their global distribution agreement
Thomson Reuters ONE - Mon Apr 08, 1:26AM CDT
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
CellaVision's 2012 Annual Report now available
Thomson Reuters ONE - Wed Apr 03, 2:01AM CDT
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
Notice of Annual General Meeting in CellaVision AB, April 24, 2013
Thomson Reuters ONE - Thu Mar 21, 2:31AM CDT
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
NeuroVive Appoints Anna Malm Bernsten and Boel Flodgren to its Board of Directors
PR Newswire - Mon Mar 18, 5:06AM CDT
NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company announces that Anna Malm Bernsten and Boel Flodgren have been elected to the Company's Board. Both have exceptional track records and leadership experience and are expected to make a significant contribution to NeuroVive.
CellaVision launches a new product for proficiency testing
Thomson Reuters ONE - Tue Mar 05, 7:01AM CST
CellaVision, which develops and sells products for routine analysis of blood and other body fluids in health care, is launching a new product for internal and external quality assurance and proficiency testing of laboratory analyses. The product, CellaVision® Proficiency Software, targets clinical laboratories that assess and perform the classification of blood cells, as well as accredited providers of external quality assessment schemes for laboratory medicine.
CellaVision adds another distribution agreement for the European market
Thomson Reuters ONE - Mon Feb 25, 5:01AM CST
This information was released for public disclosure on February 25, 2013 at 12.00 am CET.
CellaVision AB: Year-end bulletin 2012
Thomson Reuters ONE - Thu Feb 14, 1:21AM CST
Growth of 9 per cent and strengthened market position
CellaVision AB: Interim Report January-June 2014
Thomson Reuters ONE - Fri Jul 18, 1:20AM CDT
Continued strong sales growth of 50 percent
CellaVision acquires a new technology platform
Thomson Reuters ONE - Mon Jun 23, 8:01AM CDT
This information was released for public disclosure on June 23, 2014 at 3.00 pm CET.
CellaVision revises outlook for the full year: Sales growth in 2013
Thomson Reuters ONE - Wed Jan 15, 1:26AM CST
CellaVision announces that sales for the fourth quarter of 2013 has increased significantly in comparison with the corresponding quarter in 2012. This means that the company shows sales growth for the full year 2013, in contrast to what was communicated in the company's half-year report 2013.
CellaVision AB: Interim report January - June 2013
Thomson Reuters ONE - Wed Jul 17, 1:31AM CDT
Weak quarter but continued global market initiatives and sales successes in Asia
CellaVision appoints new heads of Quality Assurance and Scientific Affairs
Thomson Reuters ONE - Mon Jun 24, 1:31AM CDT
CellaVision, which develops and sells products for routine analysis of blood and other body fluids in health care services, strengthens its organization with new positions in quality and scientific affairs. Goran Granqvist has been appointed VP Quality, responsible for Quality Assurance and part of the management team. Hans-Inge Bengtsson takes a new role as Director Scientific Affairs.
Sweden's Equalis invests in CellaVision's new product for external quality assurance of laboratory tests in hematology
Thomson Reuters ONE - Tue May 07, 4:02AM CDT
CellaVision has signed an agreement with Equalis, the Swedish provider of external quality assessment for clinical laboratory tests. Equalis has chosen to invest in CellaVision's new proficiency testing program for the identification of cells in blood and other body fluids, CellaVision® Proficiency Software. The order comprises a license for 350 users.
Bulletin from the Annual General Meeting of CellaVision AB (publ) held on April 24, 2013
Thomson Reuters ONE - Wed Apr 24, 12:39PM CDT
CellaVision AB (publ) held its Annual General Meeting today, April 24, 2013, in Lund. The meeting resolved upon the following:
CellaVision AB: Interim report January - March 2013
Thomson Reuters ONE - Wed Apr 24, 7:02AM CDT
More sales channels increase our growth opportunities but the year got off to a weak start
CellaVision and Sysmex announce a jointly-developed product for hematology labs
Thomson Reuters ONE - Tue Apr 16, 8:01AM CDT
This information was released for public disclosure on April 16, 2013 at 3.00 pm CET.
CellaVision and Beckman Coulter enhance partnership by adding EMEA to their global distribution agreement
Thomson Reuters ONE - Mon Apr 08, 1:26AM CDT
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
CellaVision's 2012 Annual Report now available
Thomson Reuters ONE - Wed Apr 03, 2:01AM CDT
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
Notice of Annual General Meeting in CellaVision AB, April 24, 2013
Thomson Reuters ONE - Thu Mar 21, 2:31AM CDT
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
NeuroVive Appoints Anna Malm Bernsten and Boel Flodgren to its Board of Directors
PR Newswire - Mon Mar 18, 5:06AM CDT
NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company announces that Anna Malm Bernsten and Boel Flodgren have been elected to the Company's Board. Both have exceptional track records and leadership experience and are expected to make a significant contribution to NeuroVive.
CellaVision launches a new product for proficiency testing
Thomson Reuters ONE - Tue Mar 05, 7:01AM CST
CellaVision, which develops and sells products for routine analysis of blood and other body fluids in health care, is launching a new product for internal and external quality assurance and proficiency testing of laboratory analyses. The product, CellaVision® Proficiency Software, targets clinical laboratories that assess and perform the classification of blood cells, as well as accredited providers of external quality assessment schemes for laboratory medicine.
CellaVision adds another distribution agreement for the European market
Thomson Reuters ONE - Mon Feb 25, 5:01AM CST
This information was released for public disclosure on February 25, 2013 at 12.00 am CET.
CellaVision AB: Year-end bulletin 2012
Thomson Reuters ONE - Thu Feb 14, 1:21AM CST
Growth of 9 per cent and strengthened market position
